Several antibodies such as HuM195 (antiCD33), B4 (anti-CD19), trastuzumab (anti-HER2/neu), and J591 (anti-PSMA), which target leukemia, lymphoma, breast/ovarian cancer, and prostate cancer, respectively, were 225Ac-labeled using this procedure and tested in vivo [30]. Here, ERBB2 is linked to prostate carcinoma.